Syneron Bio Announces Strategic Collaboration with AstraZeneca to Develop First-in-Class Oral Macrocyclic Peptide Therapeutics for Chronic Diseases

2025Year3Month21Date, Beijing, China —— Innovative oral macrocycle peptide drug R&D company Syneron Bio (Syneron Bio)Today announced a collaboration with AstraZeneca, the global pharmaceutical industry leader (Astra Zeneca) to establish a strategic partnership to jointly develop global solutions for chronic diseasesFirst CreationBigCyclic PeptideClassDrugAccording to the agreement, AstraZeneca will obtain Syneron Bio.TheSynova™Original TechnologyPlatform Usage Rights.The intelligentHigh-Throughput TransformationThe macrocycle peptide drug discovery platform will help advance treatments for rare diseases, autoimmune disorders, and metabolic diseases.Sexual DiseaseInnovation in DiseaseDrug R&D。

According to the terms of the agreement, AstraZeneca will pay$75 millionFirstPayment and Recent MilestonesPayment,Total Reach$3.4 Billion in R&D and Commercialization MilestonesPayment, and pay tiered royalties based on global sales. In addition, AstraZenecaWill alsoSyneron Bio conducts equity investment.Syneron BioPlans to expand its Beijing R&D center through this collaboration.

Founder and CEO of Syneron BioZhang XiaoPh.D.Indicates:"We are very pleased to have reached a strategic cooperation with AstraZeneca. This cooperation demonstratesSynova™ Platform's Value in Innovative Drug Development. FacingAutoimmune Diseases, and other chronic diseases such as metabolic disorders, this collaboration highlights the determination of both parties to accelerate the development of drugs for chronic diseases."

AboutSyneron Bio(Syneron Bio)

Syneron Bio (Syneron Bio) Syneron Bio is a biotechnology company dedicated to developing novel macrocyclic peptide drugs, utilizing its proprietarySynova™Platform technology has established a rich and differentiated pipeline of macrocyclic peptide drugs, providing breakthrough therapeutic solutions for patients in the fields of oncology and chronic diseases worldwide.Syneron BioThe core team has extensive experience in drug development and top-tier data science technology capabilities on an international level. In less than three years, the company completed multiple rounds of equity financing, with investors including several well-known venture capital funds.

Welcome to follow: